We enable the acceleration of life science research
and development in the pursuit of improved human health

About AiPharma

AiPHARMA is an early-stage biotechnology company with regional offices in Boston, Dubai, Tokyo, Singapore and Hong Kong. We take a highly interdisciplinary approach to science, with our services building upon work from leading academic labs in biophysics and algorithmic design that enables the acceleration of life science research and development in the pursuit of improved human health.

Global Response Aid (GRA)

At the stage where COVID-19 was declared a pandemic, we quickly deployed a crew to start an initiative, that later became a full-fledged company called Global Response Aid. Alongside Agility which is one of the world’s leading logistics companies with a presence in 100 countries and annual turnover of $5BN.


PREPAiRE aims to provide reliable early warning on potential pandemics, but more importantly, to provide governments, health care professionals and business with the tools to predict, and understand the characteristics of the threat and the forecast consequences on the demand of PPE, medical devices and drugs.



NAS_logo.5a33ccaa14043 (1).png



Omar Quandeel

Chairman of the Board


David Howe
Chief Operating Officer


Ivaylo Vladimirov Tsanev

Chief Regulatory Officer


Alasdair Moore


Mary O’Brian
Chief Marketing Officer


Brett Wight
Chief Commercial Officer


Omar Arrab



John White
Group Legal Counsel


Abdulla Al Mansoori

Director of AiPharma MENA


Elvira Pleshakova
SVP Legal




September 23, 2020

Fujifilm to seek approval for Avigan in Covid-19 after positive data

Japan's Fujifilm Toyama Chemical plans to seek approval for its anti-viral drug Avigan (favipiravir) to treat patients with Covid-19, after obtaining positive results in a Phase III clinical trial.

September 23, 2020

Fujifilm's flu drug Avigan improves COVID-19 recovery time, setting up filing in Japan

Six months after the World Health Organization declared COVID-19 a global pandemic, the list of drugs with proven efficacy against the virus remains short. On Wednesday, Fujifilm added its flu drug Avigan.

September 23, 2020

Anti-influenza drug Avigan® TabletMeets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients

TOKYO, September 23, 2020—FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereinafter “FUJIFILM Toyama Chemical”) has announced today that primary endpoint has been met in phase III clinical trial of “Avigan Tablet” 

September 23, 2020

Avigan® Shows Promising Results in Treatment of COVID Patients in Japan

Healthcare solutions provider Global Response Aid (GRA) and Dr. Reddy's Laboratories (NYSE: RDY) announced that the anti-viral drug Avigan® produced promising results in a single-blinded, placebo-controlled Phase 3 clinical study conducted in Japan with the sponsorship of FujiFilm Toyama Chemical.

September 20, 2020

International Cooperation in Clinical Studies: Richard H. Kaszynski / MD, Ph.D., Co-Founder and Director of Stanford Solutions

Richard H. Kaszynski formed a global network to rapidly conduct clinical drug trials in order to fight against infectious disease pandemics. He talks about a promising drug candidate for COVID-19.

September 28, 2020

Clinical Catch-Up: September 21-25

The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.



ONE JLT Tower 14th floor
Jumeriah Lake Towers ,Dubai, 103805
United Arab Emirates

Our Projects

© 2020 by AiPharma


This Website contains statements, names and references, but not limited to past or forward-looking events or features.
Potential risks and uncertainties include factors as general usage, implementation or applications restricted by laws and regulations are part of the disclaimers.